Sparta Commercial Services (SRCO) 10-Q 17 Mar 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jan. 31, 2022	Mar. 16, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--04-30
Entity File Number	0-9483
Entity Registrant Name	SPARTA COMMERCIAL SERVICES, INC.
Entity Central Index Key	0000318299
Entity Tax Identification Number	30-0298178
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Fifth Avenue
Entity Address, Address Line Two	14th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(212)
Local Phone Number	239-2666
Title of 12(b) Security	Common stock, $.001 par value
Trading Symbol	SRCO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		14,903,005

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Current Assets
Cash and cash equivalents	$ 30,711	$ 396
Accounts receivable	2,742	469
Inventory	9,979	13,823
Total Current Assets	43,432	14,688
Property and equipment, net of accumulated depreciation and amortization of $213,262 and $212,905, respectively
Other assets	9,628	9,628
Deposits	9,000	9,000
Total assets	62,060	33,316
Current Liabilities
Bank overdraft	49,667	49,041
Accounts payable and accrued expenses	3,528,414	3,627,831
Short Term Loan	141,585	409,013
Current portion notes payable	5,230,084	4,680,275
Deferred revenue	5,514	13,946
Derivative liabilities	8,288,379	3,446,738
Total Current Liabilities	17,243,643	12,226,844
Loans payable-related parties	432,403	432,403
Total Long Term Liabilities	432,403	432,403
Total liabilities	17,676,046	12,659,247
Deficit:
Common stock, $0.001 par value; 750,000,000 shares authorized, and 14,253,005 and 9,809,877 shares issued and outstanding as of January 31 and April 30, 2021 respectively	14,473	9,810
Common stock to be issued 2,349,697 and 1,215,000, respectively	23,438	1,215
Additional paid-in-capital	52,827,502	51,351,156
Accumulated deficit	(71,466,089)	(64,993,250)
Total deficiency in stockholders’ deficit	(18,585,195)	(13,612,930)
Non-controlling interest	971,209	986,999
Total Deficit	(17,613,986)	(12,625,931)
Total Liabilities and Deficit	62,060	33,316
Series A convertible preferred stock [Member]
Deficit:
Preferred stock value	12,500	12,500
Series B convertible preferred stock [Member]
Deficit:
Preferred stock value
Series C redeemable convertible preferred stock [Member]
Deficit:
Preferred stock value	2,363	4,145
Series D redeemable convertible preferred stock [Member]
Deficit:
Preferred stock value	$ 618	$ 1,494

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Accumulated depreciation and amortization	$ 213,262	$ 212,905
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	10,000,000	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock shares issued	14,253,005	9,809,877
Common stock shares outstanding	14,253,005	9,809,877
Common stock to be issued	2,349,697	1,215,000
Series A convertible preferred stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares designated	35,850	35,850
Preferred stock, shares issued	125	125
Preferred stock, shares outstanding	125	125
Series B convertible preferred stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	1,000	1,000
Preferred stock, shares issued	57	0
Preferred stock, shares outstanding	57	0
Preferred stock, liquidation and redemption value per share	$ 10,000	$ 10,000
Series C redeemable convertible preferred stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	4,200,000	4,200,000
Preferred stock, shares issued	2,163,000	4,132,269
Preferred stock, shares outstanding	2,163,000	4,132,269
Preferred stock, liquidation and redemption value per share	$ 10	$ 10
Series D redeemable convertible preferred stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares designated	2,000,000	2,000,000
Preferred stock, shares issued	618,411	1,493,962
Preferred stock, shares outstanding	618,411	1,493,962
Preferred stock, liquidation and redemption value per share	$ 1	$ 1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2022	Jan. 31, 2021
Revenue
Total Revenue	$ 121,405	$ 53,473	$ 187,103	$ 195,027
Less Cost of goods sold	19,435	7,504	32,551	53,238
Gross profit	101,970	45,969	154,552	141,789
Operating expenses:
General and administrative	590,304	229,407	847,017	1,163,116
Depreciation and amortization
Total operating expenses	590,304	229,407	847,017	1,163,116
Loss from operations	(488,334)	(183,438)	(692,465)	(1,021,327)
Other (income) expense:
Other income	(3,297)	(5,944)	(11,356)	(6,694)
Forgiveness of debt		(62,277)		(125,330)
Financing cost	180,750	4,688	180,750	300,417
Amortization of debt discount			(40,000)
Loss (gain) in changes in fair value of derivative liability	1,062,260	0	5,990,400	1,310,307
Total other (income) expense	1,239,713	(63,533)	6,159,794	1,478,700
Income (loss) from continuing operations	(1,728,047)	(119,905)	(6,488,628)	(2,500,027)
Loss from discontinued operations
Net income (loss)	(1,728,047)	(119,905)	(6,852,259)	(2,500,027)
Net loss attributed to non-controlling interest	15,479	(903)	15,790	(6,837)
Preferred dividend			(382)	(191)
Net income (loss) attributed to common stockholders	$ (1,743,526)	$ (120,808)	$ (6,836,851)	$ (2,507,055)
Basic and diluted loss per share:
Loss from continuing operations attributable to Sparta Commercial Services, Inc. common stockholders	$ (0.13)	$ (0.02)	$ 0.55	$ (0.40)
Loss from discontinued operations attributable to Sparta Commercial Services, Inc. common stockholders
Net loss attributable to Sparta Commercial Services, Inc. common stockholders	$ (0.10)	$ (0.02)	$ 0.54	$ (0.40)
Weighted average shares outstanding	13,265,570	7,094,502	12,568,827	6,270,929
Information Technology [Member]
Revenue
Total Revenue	$ 112,691	$ 49,220	$ 168,933	$ 185,001
New World Health Brands [Member]
Revenue
Total Revenue	$ 8,714	$ 4,253	$ 18,170	$ 10,026

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Deficit (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Jan. 31, 2022	Oct. 31, 2021	Jul. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	Jul. 31, 2020	Jan. 31, 2022	Jan. 31, 2021
Beginning Balance	$ (17,192,186)	$ (11,747,580)	$ (12,625,931)	$ (12,902,572)	$ (12,783,660)	$ (11,591,617)	$ (12,625,931)	$ (11,591,617)
Issuance of preferred shares		(321,019)
Shares to be issued		696		108,000
Preferred dividend		(382)				(191)
Preferred dividends					23,333
Sale of preferred stock				45	112	70,000
Sale of common stock				191,082		20,000
Stock based compensation						464,718
Shares issued for settlement of accounts payable						311,378
Option issued for settlement of accounts payable						156,947
Shares issued for conversion of subsidiary preferred					30,765
Shares cancelled due to reverse split				(830,301)
Shares re-issue for stock split				754,047
Conversion of preferred shares	1,296,236
Issuance of shares for services	25,490						$ 25,063
Issuance of shares for services, shares							427,235
Conversion of Preferred to common stocks			373,893
Conversion of notes to common shares			25,000
Common shares issued for cash			99,318
Net loss	(1,613,986)	(5,123,901)	380,140	(120,808)	(173,122)	(2,214,895)
Ending Balance	(17,613,986)	(17,192,186)	(11,747,580)	(12,800,507)	(12,902,572)	(12,783,660)	$ (17,613,986)	(12,800,507)
Common Stock [Member]
Beginning Balance	$ 12,205	$ 11,509	$ 9,810	$ 707,126	$ 640,426	$ 627,093	$ 9,810	$ 627,093
Beginning balance, shares	12,205,353	11,508,878	9,809,877	73,104,262	6,404,262	6,270,929	9,809,877	6,270,929
Shares to be issued		$ 696
Shares tobe issued, shares		696,475
Sale of common stock				$ 15,000		$ 13,333
Sale of common stock, shares				15,000,000		133,333
Shares issued for conversion of subsidiary preferred					$ 66,700
Shares issued for conversion of subsidairy preferred, shares					66,700,000
Shares cancelled due to reverse split				$ (722,126)
Shares cancelled due to reverse split, shares				(88,104,262)
Shares re-issue for stock split				$ 709,476
Shares re-issue for stock split, shares				7,094,758
Conversion of preferred shares	$ 1,841
Conversion of preferred shares, shares	1,620,417
Issuance of shares for services	$ 427
Issuance of shares for services, shares	427,235
Conversion of Preferred to common stocks			$ 1,574
Conversion of Preferred to common stocks, shares			1,574,001
Conversion of notes to common shares			$ 125
Conversion of notes to common shares, shares			125,000
Net loss
Ending Balance	$ 14,473	$ 12,205	$ 11,509	$ 709,476	$ 707,126	$ 640,426	$ 14,473	$ 709,476
Ending balance, shares	14,253,005	12,205,353	11,508,878	7,094,758	73,104,262	6,404,262	14,253,005	7,094,758
Common Stock to be Issued [Member]
Beginning Balance	$ 22,443	$ 2,350	$ 1,215	$ 108,120	$ 84,787	$ 84,787	$ 1,215	$ 84,787
Beginning balance, shares	22,442,105	2,349,225	1,214,528	108,119,511	84,786,511	84,786,511	1,214,528	84,786,511
Issuance of preferred shares		$ (2,350)
Issuance of preferred shares, shares		2,349,225
Shares to be issued		$ 22,443		$ 55,000
Shares tobe issued, shares		22,442,105		555,000
Preferred dividends, shares					23,333,000
Preferred dividends					$ 23,333
Shares cancelled due to reverse split				$ (108,175)
Shares cancelled due to reverse split, shares				(108,674,511)
Shares re-issue for stock split				$ 44,571
Shares re-issue for stock split, shares				1,220,078
Conversion of preferred shares	$ 995
Conversion of preferred shares, shares	995,500
Common shares issued for cash			$ 1,135
Common shares issued for cash, shares			1,134,697
Net loss
Issuance of preferred shares, shares		(2,349,225)
Ending Balance	$ 23,438	$ 22,443	$ 2,350	$ 99,516	$ 108,120	$ 84,787	$ 23,438	$ 99,516
Ending balance, shares	23,437,605	22,442,105	2,349,225	1,220,078	108,119,511	84,786,511	23,437,605	1,220,078
Additional Paid-in Capital [Member]
Beginning Balance	$ 51,507,118	$ 51,847,540	$ 51,351,156	$ 50,378,075	$ 50,416,173	$ 49,406,954	$ 51,351,156	$ 49,406,954
Issuance of preferred shares		(317,979)
Shares to be issued		(22,443)		53,000
Sale of preferred stock						69,860
Sale of common stock				169,245		6,667
Stock based compensation						464,718
Shares issued for settlement of accounts payable						311,067
Option issued for settlement of accounts payable						156,947
Shares issued for conversion of subsidiary preferred					(38,098)	(40)
Conversion of preferred shares	1,295,321
Issuance of shares for services	25,063
Conversion of Preferred to common stocks			373,326
Conversion of notes to common shares			24,875
Common shares issued for cash			98,183
Net loss
Ending Balance	52,827,502	51,507,118	51,847,540	50,600,320	50,378,075	50,416,173	52,827,502	50,600,320
Retained Earnings [Member]
Beginning Balance	(69,738,042)	(64,613,448)	(64,993,250)	(65,082,461)	(64,919,397)	(62,702,339)	(64,993,250)	(62,702,339)
Preferred dividend		(382)				(191)
Shares issued for conversion of subsidiary preferred					2,163
Net loss	(1,728,047)	(5,124,212)	379,802	(119,905)	(165,227)	(2,216,867)
Ending Balance	(71,466,089)	(69,738,042)	(64,613,448)	(65,202,366)	(65,082,461)	(64,919,397)	(71,466,089)	(65,202,366)
Noncontrolling Interest [Member]
Beginning Balance	987,648	987,337	986,999	968,317	976,212	974,251	986,999	974,251
Sale of common stock				6,837
Shares issued for conversion of subsidiary preferred						(11)
Conversion of preferred shares	(960)
Net loss	(15,479)	311	338	(903)	(7,895)	1,972
Ending Balance	971,209	987,648	987,337	974,251	968,317	976,212	971,209	974,251
Series A Preferred Stock [Member] | Preferred Stock [Member]
Beginning Balance	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500	$ 12,500
Beginning balance, shares	125	125	125	125	125	125	125	125
Sale of preferred stock				$ 26
Net loss
Ending Balance	$ 12,500	$ 12,500	$ 12,500	$ 12,526	$ 12,500	$ 12,500	$ 12,500	$ 12,526
Ending balance, shares		125	125	125	125	125		125
Series B Preferred Stock [Member] | Preferred Stock [Member]
Beginning Balance
Beginning balance, shares
Net loss
Ending Balance
Ending balance, shares
Series C Preferred Stock [Member] | Preferred Stock [Member]
Beginning Balance	$ 3,160	$ 3,441	$ 4,145	$ 4,155	$ 4,145	$ 4,005	$ 4,145	$ 4,005
Beginning balance, shares	3,146,969	3,427,969	4,132,269	4,155	4,145	4,005	4,132,269	4,005
Issuance of preferred shares		$ (281)
Issuance of preferred shares, shares		281,000
Sale of preferred stock				$ 19	$ 10	$ 140
Sale of preferred stocks, shares					10	140
Conversion of preferred shares	$ (797)
Conversion of preferred shares, shares	(983,969)
Conversion of Preferred to common stocks			$ (704)
Conversion of Preferred to common stocks, shares			(704,300)
Net loss
Issuance of preferred shares, shares		(281,000)
Ending Balance	$ 2,363	$ 3,160	$ 3,441	$ 4,174	$ 4,155	$ 4,145	$ 2,363	$ 4,174
Ending balance, shares	2,163,000	3,146,969	3,427,969	4,155	4,155	4,145	2,163,000	4,155
Series D Preferred Stock [Member] | Preferred Stock [Member]
Beginning Balance	$ 782	$ 1,191	$ 1,494	$ 1,596	$ 1,494	$ 1,132	$ 1,494	$ 1,132
Beginning balance, shares	782,411	1,191,411	1,493,962	1,596	1,494	1,132	1,493,962	1,132
Issuance of preferred shares		$ (409)
Issuance of preferred shares, shares		409,000
Sale of preferred stock					$ 102
Sale of preferred stocks, shares					102
Shares issued for settlement of accounts payable						$ 311
Shares issued for settlement of accounts payable, shares						311
Shares issued for conversion of subsidiary preferred						$ 51
Shares issued for conversion of subsidairy preferred, shares						51
Conversion of preferred shares	$ (164)
Conversion of preferred shares, shares	(164,000)
Conversion of Preferred to common stocks			$ (303)
Conversion of Preferred to common stocks, shares			(302,551)
Net loss
Issuance of preferred shares, shares		(409,000)
Ending Balance	$ 618	$ 782	$ 1,191	$ 1,596	$ 1,596	$ 1,494	$ 618	$ 1,596
Ending balance, shares	618,411	782,411	1,191,411	1,596	1,596	1,494	618,411	1,596

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (6,852,259)	$ (2,500,027)
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustment on Preferred Stock A
Stock based compensation	262,466	464,718
Loss (Gain) from change in fair value of derivative liabilities	5,990,400	1,450,321
Amortization of debt discount	40,000
Non-cash financing cost	180,750	300,417
Non-cash consulting fees	90,448
Forgiveness of debt /adjustments	(190,186)	(212,049)
Changes in operating assets and liabilities
Accounts receivable	(2,273)	(14,701)
Inventory	3,844	4,644
Other assets		(1,637)
Accounts payable and accrued expenses	15,736	(399,452)
Deferred revenue	(8,432)	9,005
Net cash from (used) operating activities	(469,506)	(898,761)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment
Net cash (used in) investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Bank overdraft	(626)	(10,486)
Proceeds from sale of stock	407,500	526,002
Proceeds from notes payable		191,085
Payments on notes payable	(267,428)
Proceeds from related party notes
Payments on related party notes		219,928
Conversion of promissory notes	359,123
Net cash provided by financing activities	499,821	926,529
Net (decrease) increase in cash	30,315	27,768
Cash and cash equivalents, beginning of period	396
Cash and cash equivalents , end of period	30,711	27,768
Cash paid for:
Interest
Income taxes

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE A – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying unaudited condensed consolidated financial statements follows. Business Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City, www.spartacommercial.com. We are a multi-disciplined parent corporation operating across three business sectors – Financial Services, E-Commerce & Mobile Technology, and Health and Wellness, (www.spartacommercial.com). Sparta’s roots are in the Powersports industry. The Company provided retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing provided by institutional lenders. The Company also maintained a full underwriting and servicing platform for its portfolio. Notwithstanding the discontinuance of our initial focus on consumer loans and leases post Lehman and during the 2008 financial crisis; in 2007, the Company had introduced a new initiative, Municipal Financing, ( www.spartamunicipal.com Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness and have been sold across all 50 states and in 62 countries worldwide. They provide a trusted layer of assurance to vehicle buyers and are available on Kelley Blue Book, Auto Trader, AllState Insurance and a range of various dealership websites. They include Cyclechex (Motorcycle History Reports at www.cyclechex.com), RVchex (Recreational Vehicle History Reports at www.rvchex.com), CarVINreport (Automobile History Reports at www.carvinreport.com), and Truckchex (Heavy Duty Truck History Reports at www.truckchex.com). The Company’s E-Commerce and Mobile Technology subsidiary name change to iMobile Solutions, Inc., from Specialty Reports, Inc., in 2017, signifies its ever-broadening service offerings in the evolving technology landscape. Under iMobile App (www.imobileapp.com), the Company provides mobile technology services, including web and mobile application creation, development and management for a wide range of businesses in the achievement of their marketing goals. The Company also designs, launches, maintains and hosts websites for businesses. Sparta created its subsidiary, New World Health Brands, Inc., in April 2019, on the heels of the Agriculture Improvement Act (also known as the Farm Bill), which was signed into law the previous December 20, 2018. Consequently, hemp (CBD) was removed from Schedule 1 of the Controlled Substances Act. Company management recognized the substantial business opportunity that lay ahead in the rapidly expanding hemp-CBD (cannabidiol) market in the United States. During 2019-2020, we sourced, developed and tested 5 CBD product categories totaling 31 products. We procured premium, domestic-grade, full-spectrum, broad-spectrum, and THC free hemp, created product packaging and labeling, and implemented fulfillment to launch an online B to C website: www.newworldhealthcbd.com on December 21, 2019. To ensure the safety and quality of our products, all CBD product offerings are exclusively sourced, manufactured and tested at highly accredited testing facilities in the United States and adhere to strict U.S standards and guidelines. Sparta’s response to the onset of the COVID 19 pandemic in early 2020 quickly took shape with thorough investigations into evolving customer trends in health and wellness. As a result, we expanded New World Health Brands and developed a new product line of natural dietary supplements. In August 2020, we launched an online B to C website: www.newworldhealthbrands.com, featuring high quality dietary supplements, including vitamins and minerals, such as, Zinc, Magnesium, Boron, Iodine, Beetroot Extract, Selenium, Vitamin B Complex, Vitamin C and PQQ. To ensure the safety and quality of our products, all health and wellness offerings are exclusively sourced and manufactured in the United States and adhere to strict U.S. standards and guidelines. Sparta’s commitment to high standards and transparency are tantamount to being a trusted brand. Sparta’s newest subsidiary, Sparta Crypto, Inc., was established September 25, 2020 and is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services. The platform has not launched and the Company can make no assurances that the described plan will reach implementation. In addition, the Company has completed and tested a cryptocurrency payment gateway called SpartaPayIQ, which is functional and was formally announced on March 3, 2022. Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of January 31, 2022 and for the three and nine months periods ended January 31, 2022 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2021 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission. The results of operations for the nine months ended January 31, 2022 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2022. The condensed consolidated balance sheet as of April 30, 2021 contained herein has been derived from the audited consolidated financial statements as of April 30, 2021, but do not include all disclosures required by the U.S. GAAP. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit. Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in United States of America which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the reported period. Accordingly, actual results could differ from those estimates. Included in these estimates are assumptions about collection of accounts receivable, useful life of property and equipment, beneficial conversion feature of convertible notes payable, deferred income tax asset valuation allowances, and valuation of derivative liabilities. Revenue Recognition During the first quarter of 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606), using the cumulative-effect method. The new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption did not have an impact in our consolidated financial statements, other than the enhancement of our disclosures related to our revenue-generating activities. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions. Revenues from mobile app products and New World Health products are generally recognized upon delivery. Revenues from history reports are generally recognized upon delivery / download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery. Cash Equivalents For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Website Development Costs The Company recognizes website development costs in accordance with ASC 350-50, “Accounting for Website Development Costs.” Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not always be available. Income Taxes We utilize ASC 740 “ Income Taxes The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Stock Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation – Stock Compensation We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Inventories The Company’s inventories represent finished goods, consist of products available for sale and are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit. Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share As of January 31, 2022, 133,278,980 shares potential shares (including 12,205,353 shares to be issued on the balance sheet), were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share. Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of January 31, 2022 and April 30, 2021, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described. Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “ Accounting for Convertible Securities with Beneficial Conversion Features Reclassifications Certain reclassifications have been made to conform to prior periods’ data to the current presentation. These reclassifications had no effect on reported losses. Recent Accounting Pronouncements- In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (Topic 842) “ Leases Leases A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our unaudited condensed consolidated financial statements.

GOING CONCERN MATTERS

GOING CONCERN MATTERS	9 Months Ended
	Jan. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN MATTERS	NOTE B – GOING CONCERN MATTERS The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying unaudited condensed consolidated financial statements, the Company has incurred recurring losses and generated negative cash flows from operating activities since inception. As of January 31, 2022, the Company had an accumulated deficit of $ 71,466,089 and a working capital deficit of $ 64,993,250 . The Company’s cash balance and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the filing date of this report. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company’s existence is dependent upon management’s ability to develop profitable operations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company’s efforts will be successful. No assurance can be given that management’s actions will result in profitable operations or the resolution of its liquidity problems. The accompanying unaudited condensed consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. In order to improve the Company’s liquidity, the Company’s management is actively pursuing additional equity financing through discussions with investment bankers and private investors. There can be no assurance that the Company will be successful in its effort to secure additional equity financing.

NOTES PAYABLE AND DERIVATIVES

NOTES PAYABLE AND DERIVATIVES	9 Months Ended
	Jan. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE AND DERIVATIVES	NOTE C – NOTES PAYABLE AND DERIVATIVES The Company has outstanding numerous notes payable to various parties. The notes bear interest at rates of 5 20 SCHEDULE OF NOTES PAYABLE Notes Payable January 31, 2022 April 30, 2021 Notes convertible at holder’s option $ 2,980,848 $ 2,522,925 Notes convertible at Company’s option 335,700 335,700 Non-convertible notes payable 1,913,536 1,821,650 Subtotal 5,230,084 4,680,275 Debt discount - - Total $ 5,230,084 $ 4,680,275 Certain of the notes payable contain variable conversion rates and the conversion features are classified as derivative liabilities. The conversion prices are based on the market price of the Company’s common stock, at discounts of 30 48 The Company’s derivative financial instruments consist of embedded derivatives related to the outstanding short term Convertible Notes Payable. These embedded derivatives include certain conversion features indexed to the Company’s common stock. The accounting treatment of derivative financial instruments requires that the Company record the derivatives and related items at their fair values as of the inception date of the Convertible Notes Payable and at fair value as of each subsequent balance sheet date. In addition, under the provisions of Accounting Standards Codification subtopic 815-40, Derivatives and Hedging; Contracts in Entity’s Own Equity (“ASC 815-40”), as a result of entering into the Convertible Notes Payable, the Company is required to classify all other non-employee stock options and warrants as derivative liabilities and mark them to market at each reporting date. Any change in fair value inclusive of modifications of terms will be recorded as non-operating, non-cash income or expense at each reporting date. If the fair value of the derivatives is higher at the subsequent balance sheet date, the Company will record a non-operating, non-cash charge. If the fair value of the derivatives is lower at the subsequent balance sheet date, the Company will record non-operating, non-cash income. The change in fair value of the derivative liabilities at January 31, 2022, was calculated with the following average assumptions, using a Black-Scholes option pricing model are as follows: SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION Significant Assumptions: Risk free interest rate Ranging from 0.09 0.2 % Expected stock price volatility Ranging from 155 270 % Expected dividend payout Expected life in years Ranging from 0.25 3.0 The change in fair value of the derivative liabilities of convertible notes outstanding at April 30, 2021 was calculated with the following average assumptions, using a Black-Scholes option-pricing model are as follows: Significant Assumptions: Risk free interest rate Ranging from 1.83 2.00 % Expected stock price volatility 118 187 % Expected dividend payout 0 % Expected life in years Ranging from 0.25 2.0 During the nine months ended January 31, 2022 and 2021, the Company recorded a net loss of $ 6,852,259 and $ 2,507,055 , respectively, related to the mainly due to change in value of the derivative liabilities. Changes in derivative liability during the nine months ended January 31, 2022, and 2021 were: SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES January 31, 2021 2021 Balance, beginning of year $ 3,446,738 $ 2,802,125 Derivative liability extinguished (1,297,041 ) - Derivative financial liability arising on the issuance of convertible notes and warrants 140,014 Fair value adjustments 6,138,682 1,310,307 Balance, end of period $ 8,288,379 $ 4,252,446

LOANS PAYABLE TO RELATED PARTIE

LOANS PAYABLE TO RELATED PARTIES	9 Months Ended
	Jan. 31, 2022
Related Party Transactions [Abstract]
LOANS PAYABLE TO RELATED PARTIES	NOTE D – LOANS PAYABLE TO RELATED PARTIES As of January 31, 2022, and April 30, 2021, aggregated loans and notes payable, without demand and with no interest, to officers and directors were $ 432,403 432,403

EQUITY TRANSACTIONS

EQUITY TRANSACTIONS	9 Months Ended
	Jan. 31, 2022
Equity [Abstract]
EQUITY TRANSACTIONS	NOTE E EQUITY TRANSACTIONS Preferred Stock The Company is authorized to issue 10,000,000 0.001 35,850 100 1,000 10,000 4,200,000 10 2,000,000 1 During the nine months ended January 31, 2022, the Company: ● Converted total of 1,969,269 preferred shares C to common shares valued at $ 373,893 ● Converted a total of 3,194,418 common shares valued at $ 975,217 During the nine months ended January 31, 2021, the Company: ● Sold 150 70,000 Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock) 150 two-year 0.005 ● Issued 311 311,378 Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock 150 two-year ● Issued 51 51,000 Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock) 150 two-year 0.01 Common Stock The Company had 14,253,005 a 9,809,877 shares of common stock (after stock split effect) issued and outstanding as of January 31, 2022 and April 30, 2021, respectively. The Company had 2,349,697 and 1,215,000 shares (after stock split effect) of common classified as to be issued at January 31, 2022 and April 30, 2021. During the nine months ended January 31, 2022, the Company: ● Issued 427,235 25,063 ● Sold to four accredited investors 1,134,697 shares of common stock for cash of $ 70,000 and notes payable and accrued expenses settlement of $ 29,317.81 actual shares were not issued yet and recorded as commons stocks to be issued. ● Sold 140 Units Series C Convertible Preferred stock for $ 70,000 . Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 3 shares of the Company’s common stock) and 1.5 two -year Warrants to purchase one share of the Company’s common stock at $ 0.050 per share. ● Issued 311 Units Series D Convertible Preferred stock in settlement of $ 311,378 in accounts payable. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 4 shares of the Company’s common stock) and 1.5 two -year Warrants to purchase one share of the Company’s common stock at $ 1.00 per share. ● Issued 51 Units Series D Convertible Preferred stock upon conversion of $ 51,000 of the Company’s subsidiary’ preferred stock. Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 4 shares of the Company’s common stock) and 1.5 two -year Warrants to purchase one share of the Company’s common stock at $ 1.00 per share. ● On January 3, 2022, entered into agreements with Anthony L. Havens, the Company’s Chief Executive Officer (“Havens”) and Sandra L. Ahman, the Company’s Vice-President of Operations (“Ahman”) whereby Havens and Ahman agreed to convert debt owed to them in exchange for non-qualified stock options. ● Havens agreed to convert $ 137,465.76 of deferred salary in exchange for a stock option agreement (the “Havens Stock Option Agreement”) to purchase 1,718,322 shares of the Company’s common stock. ● Ahman agreed to convert $ 125,000 of deferred salary in exchange for a stock option agreement (the “Ahman Stock Option Agreement” and with the Havens Stock Option Agreement, the “Stock Option Agreements”) to purchase 1,562,500 shares of the Company’s common stock. ● On January 3, 2022, the Company granted to each of its two independent Directors five year options to purchase 187,500 shares of the Company’s common stock at $ 0.08 per share. The options vest in three equal tranches over three years . These options represent compensation for past service on the board. ● On January 3, 2022, the Company granted its CEO, Anthony L Havens and Vice President of Operations, Sandra L Ahman, five year options to purchase an aggregate of 750,000 shares of the Company’s common stock at $ 0.08 per share. The options vest in three equal tranches over three years ● On January 3, 2022, the Company granted to four employees, five year options to purchase an aggregate of 437,500 shares of the Company’s common stock at $ 0.08 per share. The options vest in three equal tranches over three years . During the nine months period ended January 31, 2021, the company On December 30, 2020, filed with the Secretary of State of the state of Nevada, a Certificate of Amendment to its Articles of Incorporation (the “Amendment”), attached herewith as Exhibit 3.1, and incorporated by reference. The Amendment will be effective as of December 30, 2020. On July 9, 2020, the Board of Directors of the Company declared July 30, 2020 as the effective date for the 1 for 100 reverse stock split As a result of the Reverse Stock Split, for every one hundred shares of outstanding common stock will automatically be converted into one shares of the Company’s common stock immediately prior to the opening of trading on the next business day after the Effective Date. If, as a result of the reverse split, a stockholder is left with a fractional share, that stockholder shall receive one full share in lieu of such fractional share. Immediately after the effectiveness of the reverse split, there will be 7,027,930

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Jan. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE F – FAIR VALUE MEASUREMENTS The Company follows the guidance established pursuant to ASC 820 which established a framework for measuring fair value and expands disclosure about fair value measurements. ASC 820 defines fair value as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes the following three levels of inputs that may be used: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs when there is little or no market data available, thereby requiring an entity to develop its own assumptions. The fair value hierarchy gives the lowest priority to Level 3 inputs. The table below summarizes the fair values of financial liabilities as of January 31, 2022: SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES Fair Value at Fair Value Measurement Using January 31, 2022 Level 1 Level 2 Level 3 Derivative liabilities $ 8,288,379 - - $ 8,288,379 Fair values of financial liabilities as of April 30, 2021 are as follows: Fair Value at Fair Value Measurement Using April 30, 2021 Level 1 Level 2 Level 3 Derivative liabilities $ 3,446,738 - - $ 3,446,738 The following is a description of the valuation methodologies used for these items: Derivative liabilities The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC Topic 825 “ The Fair Value Option for Financial Issuances

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jan. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE G – COMMITMENTS AND CONTINGENCIES In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (“2017 Tax Act”). Corporate taxpayers may carryback net operating losses (NOLs) originating between 2018 and 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carry forwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for 2019 and 2020 In addition, the CARES Act raises the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation Operating Lease Commitments Our executive offices are located in New York, NY. We have an agreement for use of office space at this location under a sub-lease which expired on October 31, 2019 5,100 Rent expense was $ 43,200 and $ 48,600 for the nine months periods ended January 31, 2022 and 2021, respectively. Litigation The Company is subject to legal proceedings and claims which arise in the ordinary course of its business. Sparta can make no representations about the potential outcome of such proceedings. As of January 31, 2022, we were not a party to any material pending legal proceeding except as stated below. From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. The Company has received notices dated April 1, 2016, May 13, 2016 and July 22, 2016 from two lenders claiming defaults relating to conversion requests of $ 8,365 643 5,000 55,125 27,500 On September 22, 2016, a motion for summary judgment in lieu of complaint was filed in the Supreme Court of The State of New York County of Kings, against the Company by a lender seeking: damages in the amount of $ 102,170 On October 26, 2018, a lender commenced an action in the Supreme Court of the State of New York in New York County alleging damages from unpaid principal and interest, attorney’s fees, costs, and expenses arising from a promissory note dated February 26, 2015, in the amount of $ 50,000.00

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jan. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE H – SUBSEQUENT EVENTS The Company has evaluated subsequent events for recognition and disclosure as of March 17, 2022 which is the date the financial statements were available to be issued. No other matters were identified affecting the accompanying financial statements and related disclosures.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jan. 31, 2022
Accounting Policies [Abstract]
Business	Business Sparta Commercial Services, Inc. (“Sparta,” “we,” “us,” or the “Company”) is a Nevada corporation with headquarters in New York City, www.spartacommercial.com. We are a multi-disciplined parent corporation operating across three business sectors – Financial Services, E-Commerce & Mobile Technology, and Health and Wellness, (www.spartacommercial.com). Sparta’s roots are in the Powersports industry. The Company provided retail installment loans and leases through authorized motorcycle dealerships in 33 states, with financing provided by institutional lenders. The Company also maintained a full underwriting and servicing platform for its portfolio. Notwithstanding the discontinuance of our initial focus on consumer loans and leases post Lehman and during the 2008 financial crisis; in 2007, the Company had introduced a new initiative, Municipal Financing, ( www.spartamunicipal.com Vehicle History Reports are a staple of Sparta’s E-Commerce Technology subsidiary iMobile Solutions, Inc. Whether a vehicle is intended for business or recreational use, Sparta’s Vehicle History Reports are highly regarded for accuracy and completeness and have been sold across all 50 states and in 62 countries worldwide. They provide a trusted layer of assurance to vehicle buyers and are available on Kelley Blue Book, Auto Trader, AllState Insurance and a range of various dealership websites. They include Cyclechex (Motorcycle History Reports at www.cyclechex.com), RVchex (Recreational Vehicle History Reports at www.rvchex.com), CarVINreport (Automobile History Reports at www.carvinreport.com), and Truckchex (Heavy Duty Truck History Reports at www.truckchex.com). The Company’s E-Commerce and Mobile Technology subsidiary name change to iMobile Solutions, Inc., from Specialty Reports, Inc., in 2017, signifies its ever-broadening service offerings in the evolving technology landscape. Under iMobile App (www.imobileapp.com), the Company provides mobile technology services, including web and mobile application creation, development and management for a wide range of businesses in the achievement of their marketing goals. The Company also designs, launches, maintains and hosts websites for businesses. Sparta created its subsidiary, New World Health Brands, Inc., in April 2019, on the heels of the Agriculture Improvement Act (also known as the Farm Bill), which was signed into law the previous December 20, 2018. Consequently, hemp (CBD) was removed from Schedule 1 of the Controlled Substances Act. Company management recognized the substantial business opportunity that lay ahead in the rapidly expanding hemp-CBD (cannabidiol) market in the United States. During 2019-2020, we sourced, developed and tested 5 CBD product categories totaling 31 products. We procured premium, domestic-grade, full-spectrum, broad-spectrum, and THC free hemp, created product packaging and labeling, and implemented fulfillment to launch an online B to C website: www.newworldhealthcbd.com on December 21, 2019. To ensure the safety and quality of our products, all CBD product offerings are exclusively sourced, manufactured and tested at highly accredited testing facilities in the United States and adhere to strict U.S standards and guidelines. Sparta’s response to the onset of the COVID 19 pandemic in early 2020 quickly took shape with thorough investigations into evolving customer trends in health and wellness. As a result, we expanded New World Health Brands and developed a new product line of natural dietary supplements. In August 2020, we launched an online B to C website: www.newworldhealthbrands.com, featuring high quality dietary supplements, including vitamins and minerals, such as, Zinc, Magnesium, Boron, Iodine, Beetroot Extract, Selenium, Vitamin B Complex, Vitamin C and PQQ. To ensure the safety and quality of our products, all health and wellness offerings are exclusively sourced and manufactured in the United States and adhere to strict U.S. standards and guidelines. Sparta’s commitment to high standards and transparency are tantamount to being a trusted brand. Sparta’s newest subsidiary, Sparta Crypto, Inc., was established September 25, 2020 and is in the process of completing a proprietary state-of-the-art platform designed to connect users of widely adopted digital currencies with sellers of various goods and services. The platform has not launched and the Company can make no assurances that the described plan will reach implementation. In addition, the Company has completed and tested a cryptocurrency payment gateway called SpartaPayIQ, which is functional and was formally announced on March 3, 2022.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements as of January 31, 2022 and for the three and nine months periods ended January 31, 2022 and 2020 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission, including Form 10-Q and Regulation S-K. The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments), which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. The Company believes that the disclosures provided are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and explanatory notes for the year ended April 30, 2021 as disclosed in the Company’s Form 10-K for that year as filed with the Securities and Exchange Commission. The results of operations for the nine months ended January 31, 2022 are not necessarily indicative of the results to be expected for any other interim period or the full year ending April 30, 2022. The condensed consolidated balance sheet as of April 30, 2021 contained herein has been derived from the audited consolidated financial statements as of April 30, 2021, but do not include all disclosures required by the U.S. GAAP.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The third-party ownership of the Company’s subsidiary is accounted for as noncontrolling interest in the consolidated financial statements. Changes in the noncontrolling interest are reported in the statement of changes in deficit.
Estimates	Estimates These financial statements have been prepared in accordance with accounting principles generally accepted in United States of America which require management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosures of revenues and expenses for the reported period. Accordingly, actual results could differ from those estimates. Included in these estimates are assumptions about collection of accounts receivable, useful life of property and equipment, beneficial conversion feature of convertible notes payable, deferred income tax asset valuation allowances, and valuation of derivative liabilities.
Revenue Recognition	Revenue Recognition During the first quarter of 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606), using the cumulative-effect method. The new standard requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The adoption did not have an impact in our consolidated financial statements, other than the enhancement of our disclosures related to our revenue-generating activities. The Company acts as a principal in its revenue transactions as the Company is the primary obligor in the transactions. Revenues from mobile app products and New World Health products are generally recognized upon delivery. Revenues from history reports are generally recognized upon delivery / download. Prepayments received from customers before delivery (if any) are recognized as deferred revenue and recognized upon delivery.
Cash Equivalents	Cash Equivalents For the purpose of the accompanying unaudited condensed consolidated financial statements, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents.
Website Development Costs	Website Development Costs The Company recognizes website development costs in accordance with ASC 350-50, “Accounting for Website Development Costs.”
Fair Value Measurements	Fair Value Measurements The Company has adopted ASC 820, “Fair Value Measurements .” ● Level 1 — ● Level 2 — ● Level 3 — This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. For some products or in certain market conditions, observable inputs may not always be available.
Income Taxes	Income Taxes We utilize ASC 740 “ Income Taxes The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense.
Stock Based Compensation	Stock Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation – Stock Compensation We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Inventories	Inventories The Company’s inventories represent finished goods, consist of products available for sale and are accounted for using the first-in, first-out (FIFO) method and valued at the lower of cost or net realizable value. Inventory consists of finished goods for the Company’s New World Health business.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.
Net Loss Per Share	Net Loss Per Share The Company uses ASC 260-10, “ Earnings Per Share As of January 31, 2022, 133,278,980 shares potential shares (including 12,205,353 shares to be issued on the balance sheet), were excluded from the shares used to calculate diluted earnings per share as their inclusion would reduce net loss per share.
Derivative Liabilities	Derivative Liabilities The Company assessed the classification of its derivative financial instruments as of January 31, 2022 and April 30, 2021, which consist of convertible instruments and rights to shares of the Company’s common stock and determined that such derivatives meet the criteria for liability classification under ASC 815. ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as freestanding derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “ Accounting for Derivative Instruments and Hedging Activities The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “ Accounting for Convertible Securities with Beneficial Conversion Features
Reclassifications	Reclassifications Certain reclassifications have been made to conform to prior periods’ data to the current presentation. These reclassifications had no effect on reported losses.
Recent Accounting Pronouncements-	Recent Accounting Pronouncements- In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (Topic 842) “ Leases Leases A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, we have not determined whether implementation of such proposed standards would be material to our unaudited condensed consolidated financial statements.

NOTES PAYABLE AND DERIVATIVES (

NOTES PAYABLE AND DERIVATIVES (Tables)	9 Months Ended
	Jan. 31, 2022
Debt Disclosure [Abstract]
SCHEDULE OF NOTES PAYABLE	The Company has outstanding numerous notes payable to various parties. The notes bear interest at rates of 5 20 SCHEDULE OF NOTES PAYABLE Notes Payable January 31, 2022 April 30, 2021 Notes convertible at holder’s option $ 2,980,848 $ 2,522,925 Notes convertible at Company’s option 335,700 335,700 Non-convertible notes payable 1,913,536 1,821,650 Subtotal 5,230,084 4,680,275 Debt discount - - Total $ 5,230,084 $ 4,680,275
SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION	The change in fair value of the derivative liabilities at January 31, 2022, was calculated with the following average assumptions, using a Black-Scholes option pricing model are as follows: SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION Significant Assumptions: Risk free interest rate Ranging from 0.09 0.2 % Expected stock price volatility Ranging from 155 270 % Expected dividend payout Expected life in years Ranging from 0.25 3.0 The change in fair value of the derivative liabilities of convertible notes outstanding at April 30, 2021 was calculated with the following average assumptions, using a Black-Scholes option-pricing model are as follows: Significant Assumptions: Risk free interest rate Ranging from 1.83 2.00 % Expected stock price volatility 118 187 % Expected dividend payout 0 % Expected life in years Ranging from 0.25 2.0
SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES	Changes in derivative liability during the nine months ended January 31, 2022, and 2021 were: SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES January 31, 2021 2021 Balance, beginning of year $ 3,446,738 $ 2,802,125 Derivative liability extinguished (1,297,041 ) - Derivative financial liability arising on the issuance of convertible notes and warrants 140,014 Fair value adjustments 6,138,682 1,310,307 Balance, end of period $ 8,288,379 $ 4,252,446

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jan. 31, 2022
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES	The table below summarizes the fair values of financial liabilities as of January 31, 2022: SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES Fair Value at Fair Value Measurement Using January 31, 2022 Level 1 Level 2 Level 3 Derivative liabilities $ 8,288,379 - - $ 8,288,379 Fair values of financial liabilities as of April 30, 2021 are as follows: Fair Value at Fair Value Measurement Using April 30, 2021 Level 1 Level 2 Level 3 Derivative liabilities $ 3,446,738 - - $ 3,446,738

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	9 Months Ended
	Jan. 31, 2022shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	133,278,980
Shares to be Issued [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,205,353

GOING CONCERN MATTERS (Details

GOING CONCERN MATTERS (Details Narrative) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ 71,466,089	$ 64,993,250
[custom:WorkingCapitalDeficit-0]	$ 64,993,250

SCHEDULE OF NOTES PAYABLE (Deta

SCHEDULE OF NOTES PAYABLE (Details) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Short-term Debt [Line Items]
Subtotal	$ 5,230,084	$ 4,680,275
Debt discount
Total	5,230,084	4,680,275
Notes Convertible At Holder's Option [Member]
Short-term Debt [Line Items]
Subtotal	2,980,848	2,522,925
Notes Convertible At Company's Option [Member]
Short-term Debt [Line Items]
Subtotal	335,700	335,700
Non Convertible Notes Payable [Member]
Short-term Debt [Line Items]
Subtotal	$ 1,913,536	$ 1,821,650

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES ASSUMPTIONS USING BLACK-SCHOLES OPTION (Details)	9 Months Ended	12 Months Ended
	Jan. 31, 2022	Apr. 30, 2021
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, percentage	0.09	1.83
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, percentage	0.2	2
Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, percentage	155	118
Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, percentage	270	187
Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected life	3 months	3 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, expected life	3 years	2 years
Measurement Input, Expected Dividend Rate [Member]
Debt Instrument [Line Items]
Derivative liability, measurement input, percentage		0

SCHEDULE OF CHANGES IN DERIVATI

SCHEDULE OF CHANGES IN DERIVATIVE LIABILITIES (Details) - USD ($)	9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Debt Disclosure [Abstract]
Balance, beginning of year	$ 3,446,738	$ 2,802,125
Derivative liability extinguished	(1,297,041)
Derivative financial liability arising on the issuance of convertible notes and warrants		140,014
Fair value adjustments	6,138,682	1,310,307
Balance, end of period	$ 8,288,379	$ 4,252,446

NOTES PAYABLE AND DERIVATIVES_2

NOTES PAYABLE AND DERIVATIVES (Details Narrative) - USD ($)	9 Months Ended
	Jan. 31, 2022	Jan. 31, 2021
Debt Instrument [Line Items]
Derivative loss on derivative	$ 6,852,259	$ 2,507,055
Minimum [Member]
Debt Instrument [Line Items]
Common stock discount rate, percentage	30.00%
Maximum [Member]
Debt Instrument [Line Items]
Common stock discount rate, percentage	48.00%

LOANS PAYABLE TO RELATED PART_2

LOANS PAYABLE TO RELATED PARTIES (Details Narrative) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Related Party Transactions [Abstract]
Loans payable to officers and directors	$ 432,403	$ 432,403

EQUITY TRANSACTIONS (Details Na

EQUITY TRANSACTIONS (Details Narrative) - USD ($)	Jan. 03, 2022	Dec. 30, 2020	Jan. 31, 2022	Oct. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	Oct. 31, 2020	Jan. 31, 2022	Jan. 31, 2021	Apr. 30, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized			10,000,000					10,000,000		10,000,000
Preferred stock, par value			$ 0.001					$ 0.001		$ 0.001
Number of shares issued during period				$ 696	$ 108,000
Common Stock, Shares, Outstanding			14,253,005					14,253,005		9,809,877
Common Stock, Shares, Issued			14,253,005					14,253,005		9,809,877
Number of share issued for services								427,235
Number of share issued for value			$ 25,490					$ 25,063
Stock issued during period, shares, reverse stock splits								7,027,930
Board of Directors [Member]
Class of Stock [Line Items]
Stockholders' equity, reverse stock split		1 for 100 reverse stock split
Common Stock [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares				696,475
Number of shares issued during period				$ 696
Number of share issued for services			427,235
Number of share issued for value			$ 427
Common Stock [Member] | Havens Stock Option Agreement [Member]
Class of Stock [Line Items]
Share based compensation arrangement by share based payment award options for deferred salary								$ 137,465.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								1,718,322
Common Stock [Member] | Ahman Stock Option Agreement [Member]
Class of Stock [Line Items]
Share based compensation arrangement by share based payment award options for deferred salary								$ 125,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								1,562,500
Common Stock [Member] | Four Accredited Investors [Member]
Class of Stock [Line Items]
Number of stocks sold during period								1,134,697
Sale of stock								$ 70,000
Settlement notes payable and accrued expenses			$ 29,317.81					$ 29,317.81
Common Stock [Member] | Two Independent Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	187,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years
Share Price	$ 0.08
Share based compensation vesting period	3 years
Common Stock [Member] | Chief Executive Officer And Vice President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	5 years
Share Price	$ 0.08
Share based compensation vesting period	3 years
Common Stock [Member] | Four Employees [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	437,500
Share Price	$ 0.08
Share based compensation vesting period	3 years
Common Stock to be Issued [Member]
Class of Stock [Line Items]
Number of shares issued during period, shares				22,442,105	555,000
Number of shares issued during period				$ 22,443	$ 55,000
Common Stock, Shares, Issued			2,349,697					2,349,697		1,215,000
Series A convertible preferred stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			35,850					35,850		35,850
Preferred stock, par value			$ 100					$ 100		$ 100
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			1,000					1,000
Preferred stock, liquidation preference			$ 10,000					$ 10,000
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			4,200,000					4,200,000
Preferred stock, liquidation preference			$ 10					$ 10
Conversion of common stock shares								1,969,269
Series C Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of common stock value								$ 373,893
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			2,000,000					2,000,000
Preferred stock, liquidation preference			$ 1					$ 1
Conversion of common stock shares								3,194,418
Series D Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of common stock value								$ 975,217
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of stocks sold during period									150
Sale of stock									$ 70,000
Convertible preferred stock, terms of conversion							Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 300 shares of the Company’s common stock)
Number of warrants to purchase common shares					150				150
Warrants term					2 years				2 years
Common stock, price per share					$ 0.005				$ 0.005
Series C Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Number of stocks sold during period						140
Sale of stock						$ 70,000
Convertible preferred stock, terms of conversion						Each Unit consists of 1 share of Series C Preferred stock (convertible at any time into 3 shares of the Company’s common stock)
Number of warrants to purchase common shares						1.5	1.5
Warrants term						2 years	2 years
Common stock, price per share						$ 0.050	$ 0.050
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, terms of conversion									Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock)
Number of warrants to purchase common shares					150				150
Warrants term					2 years				2 years
Common stock, price per share					$ 0.01				$ 0.01
Number of shares issued during period, shares									51
Number of shares issued during period									$ 51,000
Series D Convertible Preferred Stock [Member] | Settlement of Accounts Payable [Member]
Class of Stock [Line Items]
Convertible preferred stock, terms of conversion									Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 400 shares of the Company’s common stock
Number of warrants to purchase common shares					150				150
Warrants term					2 years				2 years
Number of shares issued during period, shares									311
Number of shares issued during period									$ 311,378
Series D Convertible Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Convertible preferred stock, terms of conversion						Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 4 shares of the Company’s common stock)
Number of warrants to purchase common shares						1.5	1.5
Warrants term						2 years	2 years
Number of shares issued during period, shares						51
Number of shares issued during period						$ 51,000
Series D Convertible Preferred Stock [Member] | Common Stock [Member] | Settlement of Accounts Payable [Member]
Class of Stock [Line Items]
Convertible preferred stock, terms of conversion						Each Unit consists of 1 share of Series D Preferred stock (convertible at any time into 4 shares of the Company’s common stock)
Number of warrants to purchase common shares						1.5	1.5
Warrants term						2 years	2 years
Common stock, price per share						$ 1	$ 1
Number of shares issued during period, shares						311
Number of shares issued during period						$ 311,378
Series D Convertible Preferred Stock One [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common stock, price per share						$ 1	$ 1

SCHEDULE OF FAIR VALUES OF FINA

SCHEDULE OF FAIR VALUES OF FINANCIAL LIABILITIES (Details) - USD ($)	Jan. 31, 2022	Apr. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 8,288,379	$ 3,446,738
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ 8,288,379	$ 3,446,738

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Sep. 22, 2016	Jan. 31, 2022	Jan. 31, 2021	Feb. 26, 2015
Tax cuts act description		The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (“2017 Tax Act”). Corporate taxpayers may carryback net operating losses (NOLs) originating between 2018 and 2020 for up to five years, which was not previously allowed under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize NOL carry forwards to offset taxable income in 2018, 2019 or 2020. Taxpayers may generally deduct interest up to the sum of 50% of adjusted taxable income plus business interest income (30% limit under the 2017 Tax Act) for 2019 and 2020
CARES act description		the corporate charitable deduction limit to 25% of taxable income and makes qualified improvement property generally eligible for 15-year cost-recovery and 100% bonus depreciation
Rent expense		$ 43,200	$ 48,600
Promissory Note [Member]
Aggregate note amount				$ 50,000
New York County Kings [Member]
Loss on contingent	$ 102,170
Lender One [Member]
Debt principal amount		8,365
Debt interest		643
Aggregate note amount		55,125
Lender Two [Member]
Debt principal amount		5,000
Aggregate note amount		$ 27,500
Executive Office Space [Member]
Lease expiring date		Oct. 31, 2019
Rent expense		$ 5,100